Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN 6: Semaglutide CV Outcomes in T2D
NCT01720446Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2013
- Primary completion
- Mar 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Feb 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01720446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01720446.